Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients.

Abstract:

:Autologous stem cell transplantation (ASCT) has an established role in the treatment of symptomatic multiple myeloma (MM). Our aim was to analyse the impact of selected prognostic parameters on the survival of patients with MM after ASCT. The new International Staging System (ISS) was also evaluated. A total of 133 MM patients were transplanted in our centre between 1995 and 2002. Following ASCT, 35% of patients were in complete remission (CR) and 60% were in partial remission (PR). The median progression-free (PFS) and overall (OS) survival from transplantation were 29.5 and 68.8 months, respectively. Transplant-related mortality (TRM) was 3%. On multivariate analysis, factors associated with significantly shorter OS were lack of CR after transplant (P = 0.002, hazard ratio (HR): 3.1), stage 3 according to ISS (P = 0.001, HR: 3.0) and age at transplant over 60 years (P = 0.035, HR: 2.0). The status of disease before ASCT did not significantly affect PFS and OS after transplantation. We conclude that ASCT is a safe and effective procedure in MM patients, associated with low TRM. The survival after ASCT was dependent on response after ASCT, stage according to ISS and age.

journal_name

Bone Marrow Transplant

authors

Krejci M,Buchler T,Hajek R,Svobodnik A,Krivanova A,Pour L,Adam Z,Mayer J,Vorlicek J

doi

10.1038/sj.bmt.1704728

subject

Has Abstract

pub_date

2005-01-01 00:00:00

pages

159-64

issue

2

eissn

0268-3369

issn

1476-5365

pii

1704728

journal_volume

35

pub_type

杂志文章
  • Autografting in Philadelphia (Ph)+ chronic myeloid leukaemia using cultured marrow: an update of a pilot study.

    abstract::Incubation of CML marrow in long-term culture (LTC) conditions may result in selection of normal (Ph-) LTC-initiating cells (LTC-IC) as early as 10 days, and in production of Ph- clonogenic cells and mature end cells within 5 weeks. This was the rationale for using marrow cells from 10-day-old LTC to autograft nine ch...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700777

    authors: Coutinho LH,Chang J,Brereton ML,Morgenstern GR,Scarffe JH,Harrison CJ,Yin JA,Darbyshire PJ,Burdach S,Dexter TM,Testa NG

    更新日期:1997-05-01 00:00:00

  • Does haploidentical transplantation in children with primary immunodeficiencies have the potential to exploit donor NK cell alloreactivity?

    abstract::Donor potential to exert NK cell alloreactivity has been shown to confer survival advantage in haploidentical hematopoietic cell transplantation for hematological malignancies. We investigated killer immunoglobulin receptor (KIR) ligand incompatibility in 40 children receiving haploidentical transplantation for primar...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704663

    authors: Dal-Cortivo L,Ouachée-Chardin M,Hirsch I,Blanche S,Fischer A,Cavazzana-Calvo M,Caillat-Zucman S

    更新日期:2004-12-01 00:00:00

  • Long-term results of selective renal shielding in patients undergoing total body irradiation in preparation for bone marrow transplantation.

    abstract::The purpose of this study was to evaluate the effect of partial renal shielding used in conjunction with total body irradiation (TBI) on the incidence of bone marrow transplantation nephropathy (BMT Np) seen as a late sequelae after transplantation. Of 402 patients who have undergone bone marrow transplantation (BMT) ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701022

    authors: Lawton CA,Cohen EP,Murray KJ,Derus SW,Casper JT,Drobyski WR,Horowitz MM,Moulder JE

    更新日期:1997-12-01 00:00:00

  • FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloablative conditioning induces regression of myelofibrosis with myeloid metaplasia.

    abstract::A 38-year-old woman with agnogenic myeloid metaplasia complicated by the poor prognostic factors of severe osteosclerosis, prominent hepatosplenomegaly, and profound anemia was treated with FLAG chemotherapy to decrease her organomegaly before undergoing a nonmyeloablative allogeneic stem cell transplant from a matche...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704172

    authors: Tanner ML,Hoh CK,Bashey A,Holman P,Sun C,Broome HE,Lane T,Ball ED,Carrier E

    更新日期:2003-09-01 00:00:00

  • Evidence of induced non-tolerance in HLA-identical twins with hemoglobinopathy after in utero fetal transplantation.

    abstract::Fetus-to-fetus transplantation has been suggested for the treatment of hemoglobinopathies in utero. However, dissimilar results have to date been obtained by different groups. We describe a case in which fetus-to-fetus transplantation in HLA-identical twins was performed at the 19th week of gestation by infusion of 0....

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Orlandi F,Giambona A,Messana F,Marino M,Abate I,Calzolari R,Damiani F,Jakil C,Renda M,Dieli F,Buscemi F,Westgren M,Ringden O,Maggio A

    更新日期:1996-09-01 00:00:00

  • Risk factors for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: retrospective analysis of 73 patients who received cyclosporin A.

    abstract::Cyclosporin A (CsA) has been used most widely as an immunosuppressive agent for preventing graft-versus-host disease (GVHD). To explore the risk factors including CsA blood levels for grades II-IV acute GVHD, we retrospectively analyzed the data of patients who underwent allogeneic hematopoietic stem cell transplantat...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705834

    authors: Izumi N,Furukawa T,Sato N,Okazuka K,Tsukada N,Abe T,Yano T,Kurasaki T,Masuko M,Toba K,Takahashi M,Aizawa Y

    更新日期:2007-11-01 00:00:00

  • Acquired factor VII deficiency in hematopoietic stem cell transplant recipients.

    abstract::Acquired factor VII (FVII) deficiency in the absence of vitamin K deficiency, oral anticoagulant therapy, synthetic liver dysfunction, or DIC is rare, with only a handful of cases thus far reported. In the period from 1990 to 1996 we identified eight patients with acquired FVII deficiency, all of whom presented with p...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703381

    authors: Toor AA,Slungaard A,Hedner U,Weisdorf DJ,Key NS

    更新日期:2002-03-01 00:00:00

  • Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma.

    abstract::A phase I/II trial evaluated early administration and dose escalation of interleukin (IL)-2 with granulocyte macrophage colony stimulating factor (GM-CSF) post-transplant. Following melphalan (200 mg/m(2)) and an autologous transplant, IL-2 was initiated (day 0) and continued for 4 weeks. GM-CSF (250 mcg/m(2)/day) beg...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705665

    authors: Meehan KR,Wu J,Bengtson E,Hill J,Ely P,Szczepiorkowski Z,Kendall M,Ernstoff MS

    更新日期:2007-06-01 00:00:00

  • Immunomagnetic depletion of CD6+ cells from bone marrow and peripheral blood.

    abstract::Depletion of donor CD6+ cells in HLA-identical allogeneic bone marrow transplantation has been reported to reduce graft-versus-host disease without interfering with engraftment. We have established an immunomagnetic cell separation technique capable of producing a 2-3 log depletion of CD6+ cells. Median recovery of CD...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Egeland T,Albrechtsen D,Martin PJ,Hansen JA

    更新日期:1990-03-01 00:00:00

  • Severe migratory polyarthritis following in vivo CAMPATH-1G.

    abstract::CAMPATH-1G is an IgG2b rat antihuman (CDw52) monoclonal antibody (MoAb) which is currently being used for T cell depletion in the setting of allogeneic bone marrow transplantation (BMT). In addition it elicits substantial lymphoid depletion, an effect which is being explored for remission induction in patients with ly...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Varadi G,Or R,Rund D,Orbach H,Slavin S,Nagler A

    更新日期:1995-12-01 00:00:00

  • Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study.

    abstract::We conducted a single-arm prospective study in 50 patients who received the combination of an haploidentical stem cell graft and an unrelated umbilical cord blood unit for the treatment of hematological malignancies. The median time for neutrophil engraftment was 13 days (11-20 days), and for platelets was 15 days (11...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.154

    authors: Chen J,Wang RX,Chen F,Sun AN,Qiu HY,Jin ZM,Tang XW,Han Y,Fu ZZ,He GS,Miao M,Ma X,Wu DP

    更新日期:2014-02-01 00:00:00

  • Granisetron in the prevention of irradiation-induced emesis.

    abstract::A double-blind double-dummy, comparative study was carried out in 30 patients receiving highly emetogenic fast dose rate, single fraction total body irradiation prior to bone marrow transplantation. Patients were randomised into one of two groups, receiving either granisetron, a specific 5-HT3 antagonist or a combinat...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Prentice HG,Cunningham S,Gandhi L,Cunningham J,Collis C,Hamon MD

    更新日期:1995-03-01 00:00:00

  • A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation.

    abstract::We initiated a randomized study of amifostine (the organic thiophosphate formerly known as WR-2721) given to patients during myeloablative conditioning therapy for allogeneic bone marrow transplantation. Amifostine was given at a dose of 1000 mg/day of conditioning and was well tolerated if attention was given to seru...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1038/sj.bmt.1704521

    authors: Hwang WY,Koh LP,Ng HJ,Tan PH,Chuah CT,Fook SC,Chow H,Tan KW,Wong C,Tan CH,Goh YT

    更新日期:2004-07-01 00:00:00

  • Clonal imbalances of serum immunoglobulins after allogeneic bone marrow transplantation: an analysis by high-resolution two-dimensional gel electrophoresis.

    abstract::The clonality pattern of immunoglobulins (Igs) produced after allogeneic bone marrow transplantation (BMT) was studied by high-resolution two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) of serum samples and purified Igs. With this technique, the light (L) chain of a monoclonal Ig usually appears as a sing...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Tissot JD,Helg C,Chapuis B,Zubler RH,Jeannet M,Hochstrasser DF,Hohlfeld P,Schneider P

    更新日期:1992-10-01 00:00:00

  • Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'-deoxycoformycin, deoxyadenosine and an immunotoxin.

    abstract::Autologous bone marrow transplantation may contribute to the treatment of several types of lymphoreticular malignancies. Recent studies have suggested that a combination of chemoseparation and immunoseparation may be more effective than either modality alone in eliminating malignant cells from human bone marrow. In th...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Montgomery RB,Kurtzberg J,Rhinehardt-Clark A,Haleen A,Ramakrishnan S,Olsen GA,Peters WP,Smith CA,Haynes BF,Houston LL

    更新日期:1990-06-01 00:00:00

  • Mesenchymal stem cells: heading into the clinic.

    abstract::In recent years, there has been an increasing interest in non-hematopoietic pluripotent progenitor cells that are found in the bone marrow. Mesenchymal stem cells (MSCs) are the first non-hematopoietic progenitors to be isolated from the bone marrow and extensively characterized. In addition to their ability to suppor...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1702791

    authors: Koç ON,Lazarus HM

    更新日期:2001-02-01 00:00:00

  • N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation.

    abstract::Busulfan is currently used as a main component in the conditioning regimen prior to allogeneic stem cell transplantation (SCT). Several studies have shown a correlation between exposure to busulfan and transplantation-related liver toxicity, such as venoocclusive disease (VOD) in patients undergoing SCT. Busulfan is m...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704143

    authors: Sjöö F,Aschan J,Barkholt L,Hassan Z,Ringdén O,Hassan M

    更新日期:2003-08-01 00:00:00

  • Are there roles for observational database studies and structured quantification of expert opinion to answer therapy controversies in transplants?

    abstract::Approaches to determine whether one transplant-related therapy is better than another include: (1) using experimental data, such as those from randomized controlled trials (RCTs); (2) using observational data, such as those from observational databases (ODBs) and (3) using conclusions from the structured quantificatio...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.447

    authors: Gale RP,Eapen M,Logan B,Zhang MJ,Lazarus HM

    更新日期:2009-03-01 00:00:00

  • Trajectories of acute graft-versus-host disease and mortality in critically ill allogeneic-hematopoietic stem cell recipients: the Allo-GRRR-OH score.

    abstract::Acute graft-versus-host disease (aGVHD) is a major cause of morbidity mortality in critically ill hematopoietic stem cell transplantation recipients. We assessed aGVHD trajectories in 191 allogeneic-HSCT recipients (age 42 (27-46)) admitted to our ICU between 2005 and 2015. aGVHD affected 130 (68%) patients (including...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-0857-x

    authors: Pichereau C,Lengliné E,Valade S,Michonneau D,Ghrenassia E,Lemiale V,Socié G,Azoulay E

    更新日期:2020-10-01 00:00:00

  • Gut protection by palifermin during autologous haematopoietic SCT.

    abstract::Conditioning therapy in connection with haematopoietic SCT (HSCT) induces a disruption of the intestinal barrier function facilitating the permeation of bacteria and endotoxin through the bowel wall with subsequent increased risk of septicaemia and a worsening of GVHD in the allogeneic setting. Palifermin (recombinant...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.388

    authors: Johansson JE,Hasséus B,Johansson P,Eklöf C,Ohman D,Stockelberg D

    更新日期:2009-05-01 00:00:00

  • Characterization of chemotherapy mobilized peripheral blood progenitor cells for use in autologous stem cell transplantation.

    abstract::Twenty patients were treated with chemotherapy to mobilize progenitors into the blood. Peripheral blood stem cells were quantitated in peripheral blood or leukapheresis products using colony assays and flow cytometric measurement of CD34+ cells. In four patients where complete sets of serial samples were obtained, the...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Bender JG,Williams SF,Myers S,Nottleman D,Lee WJ,Unverzagt KL,Walker D,To LB,Van Epps DE

    更新日期:1992-09-01 00:00:00

  • A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.

    abstract::We studied the effects of escalating doses of recombinant human IL-1 beta in patients receiving high-dose chemotherapy and ABMT for metastatic breast cancer or malignant melanoma. Sixteen patients received IL-1 beta, 4 to 32 ng/kg/day administered subcutaneously for 7 days beginning 3 h after bone marrow infusion. Thr...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1700633

    authors: Elkordy M,Crump M,Vredenburgh JJ,Petros WP,Hussein A,Rubin P,Ross M,Gilbert C,Modlin C,Meisenberg B,Coniglio D,Rabinowitz J,Laughlin M,Kurtzberg J,Peters WP

    更新日期:1997-02-01 00:00:00

  • A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group.

    abstract::The purpose of the study was to evaluate the effect of lisofylline (LSF) on engraftment, regimen-related toxicities (RRT), and mortality in patients undergoing allogeneic bone marrow transplantation (BMT). We performed a multicenter, randomized placebo-controlled trial in 60 patients with hematologic malignancies rece...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1038/sj.bmt.1702114

    authors: List AF,Maziarz R,Stiff P,Jansen J,Liesveld J,Andrews F,Schuster M,Wolff S,Litzow M,Karanes C,Dahlberg S,Kirkhart B,Bianco JA,Singer JW

    更新日期:2000-02-01 00:00:00

  • Outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome.

    abstract::HLA-identical sibling donor transplantation remains the treatment of choice for Wiskott-Aldrich Syndrome (WAS). Since 1990, utilization of alternative donor sources has increased significantly. We report the hematopoietic cell transplantation (HCT) outcomes of 47 patients with WAS treated at a single center since 1990...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2012.31

    authors: Shin CR,Kim MO,Li D,Bleesing JJ,Harris R,Mehta P,Jodele S,Jordan MB,Marsh RA,Davies SM,Filipovich AH

    更新日期:2012-11-01 00:00:00

  • Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT.

    abstract::CY in combination with BU is a widely used conditioning regimen for haematopoietic SCT (HSCT). The aim of this study was to evaluate the pharmacokinetics (PK) of CY and its major metabolite 4-hydroxyCY (HCY) in patients with thalassemia undergoing HSCT. A total of 55 patients received BU (16 mg/kg) followed by CY (160...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2011.254

    authors: Balasubramanian P,Desire S,Panetta JC,Lakshmi KM,Mathews V,George B,Viswabandya A,Chandy M,Krishnamoorthy R,Srivastava A

    更新日期:2012-09-01 00:00:00

  • Cataracts in patients receiving stem cell transplantation after conditioning with total body irradiation.

    abstract::One hundred and ninety-three patients with hematological malignancies and a follow-up > or =1 year, treated with stem cell transplantation (45 autologous, 99 allogeneic T cell-depleted matched, 49 allogeneic T cell-depleted mismatched) from July 1985 to May 1998, were considered evaluable for the development of catara...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703400

    authors: Aristei C,Alessandro M,Santucci A,Aversa F,Tabillo A,Carotti A,Latini RA,Cagini C,Latini P

    更新日期:2002-03-01 00:00:00

  • Growth, growth hormone and final height after BMT. Possible recovery of irradiation-induced growth hormone insufficiency.

    abstract::The aim of the present study was to assess growth, final height, growth hormone (GH) secretion and growth factors after BMT including TBI in childhood. The median age of the 25 participants was 11.3 years at BMT, and a median of 7.5 years had elapsed since BMT. The median height standard deviation score (SDS) declined...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Holm K,Nysom K,Rasmussen MH,Hertz H,Jacobsen N,Skakkebaek NE,Krabbe S,Müller J

    更新日期:1996-07-01 00:00:00

  • Syngeneic peripheral blood stem cell transplantation with brief immunosuppression for severe aplastic anemia.

    abstract::We report the cases of two severe aplastic anemia (SAA) patients who were successfully treated with syngeneic peripheral blood stem cell transplantation (PBSCT) using immunosuppression without high-dose chemotherapy or irradiation for conditioning. A 21-year-old woman with SAA of 6 years duration had been transfused h...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702150

    authors: Hwang WL,Yang Y,Chen GR,Tsai CS,Jour JH

    更新日期:2000-02-01 00:00:00

  • Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL.

    abstract::We investigated the prognostic relevance of IKZF1 deletions in 118 adult Ph-positive ALL patients who had minimal residual disease (MRD) data under a uniform treatment of allo-SCT following first-line imatinib-based chemotherapy. IKZF1 deletions were identified in 93 patients (78.8%). IKZF1-deleted patients had a lowe...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2014.281

    authors: Kim M,Park J,Kim DW,Kim YJ,Jeon YW,Yoon JH,Shin SH,Yahng SA,Lee SE,Cho BS,Eom KS,Kim HJ,Min CK,Cho SG,Kim Y,Lee JW,Han K,Min WS,Lee S

    更新日期:2015-03-01 00:00:00

  • Mesenchymal stromal cells: a novel and effective strategy for facilitating engraftment and accelerating hematopoietic recovery after transplantation?

    abstract::MSCs are multipotent cells that can be isolated from several human tissues and expanded ex vivo for clinical use. They comprise a heterogeneous population of cells, which, through production of growth factors, cell-to-cell interactions and secretion of matrix proteins, has a role in the regulation of hematopoiesis. In...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2011.102

    authors: Bernardo ME,Cometa AM,Locatelli F

    更新日期:2012-03-01 00:00:00